Stocks Pfizer Inc

More

  • The Federal Reserve agreed to slow down the pace of a $1.25 trillion program to buy mortgage securities, according to minutes from the FOMC meeting. Clem Chambers, CEO of ADVFN and Charles Crane, managing director at Douglass Winthrop Advisors discussed their views on the minutes of the Fed meeting.

  • Following my post earlier this week on the highest yielding stocks in the Dow, here is a deeper look at the dividends of the S&P 500.

  • Stocks fell on Tuesday after the Dow closed near the 10,000 mark on Monday. What is the best move for investors now? Roy Williams, CEO of Prestige Wealth Management, and Bill Smead, CEO and CIO of Smead Capital Management, shared their investment insights.

  • Two and a half months away from the end of the year and the average dividend yield of the Dow 30 has continued to fall since the market lows.  See how the 30 companies in the Dow compare.

  • Matt Shapiro of Stutland Equities and Bernie McSherry of Cuttone & Co. are newly optimistic on the stock markets. They explained their thinking to CNBC.

  • Stocks ended lower Friday as a dismal jobs report capped a string of disappointing economic reports this week, which cast doubt on the recovery. It was the market's second straight down week in which stocks have lost more than 3 percent.

  • Stocks tried to push higher Friday as the dollar's retreat helped the market but investors remained worried about the recovery in the wake of some disappointing economic reports.

  • Stocks opened lower Friday after disappointing reports on jobs and manufacturing.

  • Stock index futures plunged as September nonfarm payroll declines were far worse than Wall Street estimates.

  • Plus, get calls on IPOs and more.

  • Twitter

    The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.

  • Stocks advanced Tuesday as the two-year Treasury auction was met with solid demand and the dollar retreated.

  • Stocks advanced Tuesday as the two-year Treasury auction was met with solid demand and the dollar retreated.

  • Stocks advanced Tuesday as the dollar turned lower once again, boosting commodity and other stocks.

  • When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.

  • The Crisis: 1 Year Later - A CNBC Special Report - See Complete Coverage

    While market volume is picking up, there seems to be a visible lack of volatility. Is it a calm before the storm or is it a sign that things are settling down and the rally is for real? Dan Deming, trader at Stutland Equities, and Jeffrey Saut, chief investment strategist at Raymond James, shared their investor insights.

  • Tomorrow I'll be hanging out at the BioCentury/Thomson Reuters "Newsmakers in the Biotech Industry" conference in NYC, so I won't be able to monitor the webcast of an FDA panel meeting for a most intriguing drug.

  • lilly_hq.jpg

    Surely, Eli Lilly didn't throw it's restructuring plan together in a couple of weeks, but it was just the end of last month when Leerink Swann analyst Seamus Fernandez said LLY needed to cut costs and/or do a big deal. So, kudos to him for getting out ahead of it.

  • One year ago on Sunday September 14, Lehman Brothers was scrambling before declaring bankruptcy later that night and Bank of America announced a deal to acquire Merrill Lynch.  Here is a look at where major indices and stocks look one year later.

  • Look to investing in high quality stocks in this type of market environment, said Donald Yacktman, president and co-CIO of Yacktman Asset Management. He shared his market strategy and stock picks with investors.